Does simvastatin reduce coronary atherosclerotic plaque volume in male patients with hypercholesterolemia and ischemic heart disease?
Lipid-lowering therapy with simvastatin 40 mg/d for 12 months significantly reduces coronary atherosclerotic plaque volume as measured by intravascular ultrasound.
Background— Angiography of the coronary arteries reflects only changes in luminal dimensions. With intravascular ultrasound, cross-sectional images can be obtained and area measurements can be added to calculate volumes of the external elastic membrane (EEM), plaque plus media (P+M), and lumen. The aim of this study was to investigate the effect of lipid lowering by simvastatin on coronary atherosclerotic P+M as changes in volumes of EEM, P+M, and lumen. Methods and Results— In 40 male patients with hypercholesterolemia, ischemic heart disease, and a nonsignificant coronary artery lesion in a not previously revascularized coronary artery, serial intravascular ultrasound studies with an ECG-triggered pullback were performed at baseline, after 3 months on a lipid-lowering diet, and after another 12 months on simvastatin 40 mg/d. Mean length of the analyzed atherosclerotic segments was 5.9±3.3 mm. After 12 months on simvastatin, a significant reduction in P+M volume of 6.3% ( P =0.002) was observed, whereas only a nonsignificant reduction in EEM volume of 1.8% was seen without any concomitant change in lumen volume. A significant reduction in total cholesterol of 31.0% (6.1±0.8 versus 4.2±0.7 mmol/L, P <0.001) and LDL cholesterol of 42.6% (4.0±0.8 versus 2.2±0.6 mmol/L, P <0.001) was obtained. Conclusions— Lipid-lowering therapy with simvastatin for 12 months is associated with a significant P+M regression in coronary arteries measured as reduction in P+M and EEM volumes without any concomitant change in lumen volume.
Jensen et al. (Wed,) studied this question.